In the phase II study, talazoparib monotherapy elicited pCR rates that were comparable to those observed with combination anthracycline and taxane-based chemotherapy regimens when used in the neoadjuvant settings in patients with BRCA1/2 positive, early HER2-negative BC (114). This evidence concerns the gene ERBB2 and breast cancer.